Frank Torti
Frank Torti, MD
Business and Management
CDBIO
Canada
Biography
Dr. Frank Torti joined NEA in 2007 and is a Partner focused on investments in biopharmaceuticals, medical devices, and healthcare services. He has been actively involved in the firm’s investments in healthcare, includingAnnexon Biosciences, Alimera Sciences, Cadence Pharmaceuticals (acquired by Mallinckrodt plc), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), Dermira, Eargo, GST Clinics, Galera Therapeutics, Neotract, Novast Pharmaceuticals, Orphomed, Peplin (acquired by LEO Pharma), Rigel, Solta Medical (acquired by Valeant), and Tarveda Therapeutics. Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti received his medical degree from the University of North Carolina School of Medicine, his MBA with distinction from Harvard Business School, and his BA with highest honors from the University of North Carolina, where he was a Morehead Scholar.
Research Interest
Business and Management
